RT Journal Article
T1 Transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: Results from the global valve-in-valve registry.
A1 Dvir, Danny
A1 Webb, John
A1 Brecker, Stephen
A1 Bleiziffer, Sabine
A1 Hildick-Smith, David
A1 Colombo, Antonio
A1 Descoutures, Fleur
A1 Hengstenberg, Christian
A1 Moat, Neil E
A1 Bekeredjian, Raffi
A1 Napodano, Massimo
A1 Testa, Luca
A1 Lefevre, Thierry
A1 Guetta, Victor
A1 Nissen, Henrik
A1 Hernández, José-María
A1 Roy, David
A1 Teles, Rui C.
A1 Segev, Amit
A1 Dumonteil, Nicolas
A1 Fiorina, Claudia
A1 Gotzmann, Michael
A1 Tchetche, Didier
A1 Abdel-Wahab, Mohamed
A1 Marco, Federico de
A1 Baumbach, Andreas
A1 Laborde, Jean-Claude
A1 Kornowski, Ran
K1 Insuficiencia de la Válvula Aórtica
K1 Estenosis de la Válvula Aórtica
K1 Enfermedad de la Arteria Coronaria
K1 Implantación de Prótesis de Válvulas Cardíacas
K1 Prótesis Valvulares Cardíacas
K1 Cateterismo Venoso Central
K1 Resultado del Tratamiento
K1 Bioprosthesis
K1 Transcatheter aortic valve implantation
K1 Valve-in-valve
AB BACKGROUNDTranscatheter aortic valve-in-valve implantation is an emerging therapeutic alternative for patients with a failed surgical bioprosthesis and may obviate the need for reoperation. We evaluated the clinical results of this technique using a large, worldwide registry.METHODS AND RESULTSThe Global Valve-in-Valve Registry included 202 patients with degenerated bioprosthetic valves (aged 77.7±10.4 years; 52.5% men) from 38 cardiac centers. Bioprosthesis mode of failure was stenosis (n=85; 42%), regurgitation (n=68; 34%), or combined stenosis and regurgitation (n=49; 24%). Implanted devices included CoreValve (n=124) and Edwards SAPIEN (n=78). Procedural success was achieved in 93.1% of cases. Adverse procedural outcomes included initial device malposition in 15.3% of cases and ostial coronary obstruction in 3.5%. After the procedure, valve maximum/mean gradients were 28.4±14.1/15.9±8.6 mm Hg, and 95% of patients had ≤+1 degree of aortic regurgitation. At 30-day follow-up, all-cause mortality was 8.4%, and 84.1% of patients were at New York Heart Association functional class I/II. One-year follow-up was obtained in 87 patients, with 85.8% survival of treated patients.CONCLUSIONSThe valve-in-valve procedure is clinically effective in the vast majority of patients with degenerated bioprosthetic valves. Safety and efficacy concerns include device malposition, ostial coronary obstruction, and high gradients after the procedure.
PB American Heart Association
SN 0009-7322
YR 2012
FD 2012-11-06
LK http://hdl.handle.net/10668/1270
UL http://hdl.handle.net/10668/1270
LA en
NO Dvir D, Webb J, Brecker S, Bleiziffer S, Hildick-Smith D, Colombo A, et al. Transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: Results from the global valve-in-valve registry. Circulation. 2012; 126(19):2335-2344
NO Journal Article."Comment inValvular disease: Aortic valve-in-valve replacement. [Nat Rev Cardiol. 2012]Valve in valve: another milestone for transcatheter valve therapy. [Circulation. 2012]". (Nota tomada de PubMed)
DS RISalud
RD Apr 7, 2025